Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network

Por: Wolff, M (Wolff, Marcelo)¹; Shepherd, BE (Shepherd, Bryan E.)²,³; Cortes, C (Cortes, Claudia)¹; Rebeiro, P (Rebeiro, Peter)²,³; Cesar, C (Cesar, Carina)⁴; Cardoso, SW (Cardoso, Sandra Wagner)⁸; Pape, JW (Pape, Jean W.)⁶; Padgett, D (Padgett, Denis)⁷; Sierra-Madero, J (Sierra-Madero, Juan)⁸; Echevarria, J (Echevarria, Juan)⁹...Más

Autoría conjunta: Caribbean Cent South Amer Network

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Volumen: 71
Número: 1
Páginas: 102-110
DOI: 10.1097/QAI.0000000000000817
Fecha de publicación: JAN 1 2016
Ver información de revista

Resumen

Background: HIV-infected persons in resource-limited settings may experience high rates of antiretroviral therapy (ART) change, particularly because of toxicity or other nonfailure reasons. Few reports address patient outcomes after these modifications.

Methods: HIV-infected adults from the 7 Caribbean, Central and South America network clinical cohorts who modified >1 drug from the first ART regimen (ART-1) for any reason thereby starting a second regimen (ART-2) were included. We assessed cumulative incidence of, and factors associated with, death, virologic failure (VF), and regimen change after starting ART-2.

Results: Five thousand five hundred sixty-five ART-naive highly active ART initiators started ART-2 after a median of 9.8 months on ART-1; 39% changed to ART-2 because of toxicity and 11% because of failure. Median follow-up after starting ART-2 was 2.9 years; 45% subsequently modified ART-2. Cumulative incidences of death at 1, 3, and 5 years after starting ART-2 were 5.1%, 8.4%, and 10.5%, respectively. In adjusted analyses, death was associated with older age, clinical AIDS, lower CD4 at ART-2 start, earlier calendar year, and starting ART-2 because of toxicity (adjusted hazard ratio = 1.5 vs. failure, 95% confidence interval: 1.0 to 2.1). Cumulative incidences of VF after 1, 3, and 5 years were 9%, 19%, and 25%. In adjusted analyses, VF was associated with younger age, earlier calendar year, lower CD4 at the start of ART-2, and starting ART-2 because of failure (adjusted hazard ratio = 2.1 vs. toxicity, 95% confidence interval: 1.5 to 2.8).

Conclusions: Among patients modifying the first ART regimen, risks of subsequent modifications, mortality, and virologic failure were high. Access to improved antiretrovirals in the region is needed to improve initial treatment success.
Palabras clave

Palabras clave de autor: antiretroviral agents; treatment failure; cohort studies; Latin America; Caribbean region

KeyWords Plus: HIV-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITORS; RESOURCE-LIMITED SETTINGS; HIV-1-INFECTED PATIENTS; INCOME COUNTRIES; LIFE EXPECTANCY; 1ST-LINE ART; THERAPY; FAILURE; COHORT

Información del autor

Dirección para petición de copias: McGowan, CC (autor para petición de copias)

Vanderbilt Univ, Med Ctr, Div Infect Dis, A2200 Med Ctr North, Nashville, TN 37232 USA.

Direcciones:

[ 1 ] Univ Chile, Fac Med, Fdn Arriaran, Santiago 7, Chile
[ 2 ] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA
[ 5 ] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil
[ 7 ] Inst Hondureno Seguridad Social & Hosp Escuela, Tegucigalpa, Honduras
[ 8 ] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico

Direcciones de correo electrónico: c.mcgowan@vanderbilt.edu

Financiación

<table>
<thead>
<tr>
<th>Entidad financiadora</th>
<th>Número de concesión</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institute of Allergy and Infectious Diseases (NIAID) as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA)</td>
<td>U01 AI069923</td>
</tr>
<tr>
<td>Merck Sharp Dohme</td>
<td></td>
</tr>
<tr>
<td>Jansen</td>
<td></td>
</tr>
<tr>
<td>Stendahl</td>
<td></td>
</tr>
<tr>
<td>ViiV</td>
<td></td>
</tr>
<tr>
<td>Bristol-Meyers Squibb</td>
<td></td>
</tr>
<tr>
<td>Gilead</td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td></td>
</tr>
</tbody>
</table>